Etrolizumab versus Infliximab for the treatment of moderately to severely active ulcerative colitis:
The β7 integrin antibody etrolizumab was not superior to infliximab in a head-to-head phase 3 trial, but performed similarly from a clinical point of view.
Antibiotics followed by orally administered FMT was associated with induction of remission in a pilot trial. It was also effective to mediate remission in a small explorative cohort.
ADA production was increased in patients treated with cephalosporins or penicillins plus beta-lactamase inhibitors, but decreased following macrolides or fluorchinolones in an Israelian patient cohort.
Updated efficacy and safety data of atezolizumab plus bevacizumab versus sorafenib in unresectable hepatocellular carcinoma:
Even after an additional 12-months follow-up of the IMbrave150 study, atezolizumab plus bevacizumab maintained clinically meaningful survival benefits over sorafenib. After a median 15.6 (range, 0–28.6) months of follow-up, the median overall survival was 19.2 months (95% confidence interval : 17.0–23.7) with atezolizumab plus bevacizumab and 13.4 months (95% CI: 11.4–16.9) with sorafenib (hazard ratio = 0.66; 95% CI: 0.52–0.85; descriptive p < 0.001).
International Autoimmune Hepatitis Group proposes criteria for response to therapy in autoimmune hepatitis:
A consensus process initiated by the International Autoimmune Hepatitis Group (IAIHG) proposes the following criteria: Complete biochemical response: normalization of serum transaminases and immunoglobulin G (IgG) below the upper limit of normal at 6 months after initiation of treatment.Insufficient response by 6 months: failure to meet the above definition.Non-response: < 50% decrease of serum transaminases within 4 weeks after initiation of treatment.Remission: liver histology with a Hepatitis Activity Index < 4/18.Intolerance to treatment: any adverse event possibly related to treatment leading to potential drug discontinuation.
The best candidates for nucleos(t)ide analogue withdrawal are virally suppressed, HBeAg-negative, non-cirrhotic patients with low HBsAg levels, particularly Whites with < 1000 IU/ml and Asians with < 100 IU/ml. However, strict surveillance is recommended to prevent deterioration.
Oesophagus Stomach Duodenum
Budesonide oral suspension (2 mg twice daily) was superior to placebo in improving histologic, symptomatic and endoscopic outcomes over 12 weeks in a randomized phase 3 trial involving 318 patients.
A translationalstudy revealed that H. pylori infection negatively affects the response to cancer immunotherapies and suggests that H. pylori serology may be a powerful tool to personalize cancer immunotherapies.
Recovery from metabolic syndrome was associated with a reduced risk to develop pancreatic cancer in a nationwide cohort study from Korea.